Real-World & Late Phase Strategy

Finding the right approach for the right questions

Healthcare stakeholders are increasingly seeking real-world evidence to support regulatory, reimbursement and prescribing decisions, but different stakeholders demand different types and rigors of evidence. No matter the approach or research question, we have you covered to maximize value and contain costs in real world and late phase research.

promo_men talking

Industry-leading comparative effectiveness expertise

Quintiles led the development of the GRACE checklist which is formally acknowledged by the National Institute for Health and Care Excellence (NICE) and, taken on as a standard for required reporting by the Journal of Managed Care and Specialty Pharmacy.

Develop the best real-world evidence portfolio

Peri- and post-approval, your product raises new questions for regulators, payers, providers and patients. As stakeholders seek evidence to support healthcare decisions, real-world and late phase research becomes critical to the success of your product. New studies need to provide answers while factoring in emerging scientific standards for design, operations, analysis and quality assurance.

Quintiles Scientific Affairs: The right choice for real-world scientific expertise

Comprehensive evidence development: Take advantage of industry-leading expertise

Having an experienced partner at your side is of the utmost importance as you build your evidence portfolio. Quintiles offers comprehensive evidence development in the full range of observational and real-world research so that you can fully demonstrate the safety, effectiveness and quality of your product to key stakeholders.

  • Patient registries – Experience in conducting product, disease and pregnancy registries.
  • Quality of life and patient-reported outcomes – Real-world evidence to support benefits/claims in product labeling.
  • Safety outcomes/REMS – Safety and risk monitoring over longer periods of time; also monitoring off-label use.
  • Comparative effectiveness – Studies to provide evidence of effectiveness in different populations.
  • Health outcomes/health economics – Critical support for formulary approval or reimbursement efforts.
  • Real-world data for healthcare decision making – Our databases and healthcare data networks consist of more than 18 million patient records.

The power of possibilities

Quintiles has delivered more than 625 Real-World & Late Phase Programs, involving more than 96,000 sites and more than 810,000 enrolled patients in more than 100 countries since 2011.

Related Services

Quintiles has delivered more than 625 Real-World & Late Phase Programs.
Quintiles has access to more than 18M patient lives from hospital data in the COMPASS network.
More than 19M patients in observational and quality improvement programs in more than 100 countries since 2004
Quintiles Expert

Global Chief of Scientific Affairs and Senior Vice President, Real-World & Late Phase Research

Recent thinking: Amazing GRACE

Vice President, Global Head of Risk Management, Real-World & Late Phase Research

Recent thinking: Adaptive pathways offer hope to meeting patients needs faster